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CASE REPORT Open Access
Epilepsia partialis continua complicated by
disseminated tuberculosis and
hemophagocytic lymphohistiocytosis: a
case report
Gashirai K. Mbizvo1,2* , Isabel C. Lentell3, Clifford Leen4, Huw Roddie5, Christopher P. Derry2,6,
Susan E. Duncan1,2 and Kristiina Rannikmäe7
Abstract
Background: We describe a patient copresenting with epilepsia partialis continua, tuberculosis, and hemophagocytic
lymphohistiocytosis. To our knowledge, this is the first documented case of this triad.
Case presentation: A 54-year-old black South African woman presented to a hospital in Scotland with an acute history
of right-sided facial twitching, breathlessness, and several months of episodic night sweats. Clinical examination revealed
pyrexia and continuous, stereotyped, right-sided facial contractions. These worsened with speech and continued
through sleep. A clinical diagnosis of epilepsia partialis continua was made, and we provide a video of her seizures.
Computed tomographic imaging of the chest and serous fluid analyses were consistent with a diagnosis of
disseminated Mycobacterium tuberculosis. An additional diagnosis of hemophagocytic lymphohistiocytosis was made
following the identification of pancytopenia and hyperferritinemia in peripheral blood, with hemophagocytosis evident
in bone marrow investigation. We provide images of her hematopathology. The patient was extremely unwell and was
hospitalized for 6 months, including two admissions to the intensive care unit for ventilatory support. She was treated
successfully with high doses of antiepileptic drugs (benzodiazepines, levetiracetam, and phenytoin) and 12months of
oral antituberculosis therapy, and she underwent chemotherapy with 8 weeks of etoposide and dexamethasone for
hemophagocytic lymphohistiocytosis, followed by 12months of cyclosporine and prednisolone.
Conclusions: This combination of pathologies is unusual, and this case report helps educate clinicians on how such a
patient may present and be managed. A lack of evidence surrounding the coexpression of this triad may represent
absolute rarity, underdiagnosis, or incomplete case ascertainment due to early death caused by untreated tuberculosis
or hemophagocytic lymphohistiocytosis. Further research is needed.
Keywords: Epilepsia partialis continua, Epilepsy, Seizures, Etoposide, Anticonvulsants, Immunosuppression, Hemophagocytic
lymphohistiocytosis, Macrophage activation syndrome, Tuberculosis, Status epilepticus
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Background
Epilepsia partialis continua (EPC) is a rare seizure dis-
order usually considered a focal status epilepticus, with a
prevalence of less than 1 per 1 million population [1].
The diagnosis is often overlooked because of the
extended course of the condition, wherein the usual
manifestation of epilepsy as paroxysmal events is entirely
replaced by a sustained and prolonged repetition of
seizure fragments in rapid succession. These symptoms
can continue uninterrupted for days to months or even
years [2]. This makes EPC extremely disabling for
patients. It is important to correctly identify EPC
because it can indicate serious underlying pathology [3],
including vascular disorders (thromboembolic disease,
intracranial bleeds, and vasculitis) in 15–25% of cases,
central nervous system (CNS) inflammation or infection
(human immunodeficiency virus [HIV], herpes simplex
encephalitis, cat scratch disease, Japanese encephalitis, and
neurocysticercosis) in 3–45% [2], neoplasms in 5–19%, and
metabolic disorders (diabetic ketoacidosis, hepatic ence-
phalopathy, and hyponatremia) in 0–48% [1, 2, 4–9]. In
23% of EPC cases, the cause remains unknown [1, 2, 4–9].
We report an unusual syndrome of EPC complicated by
disseminated tuberculosis (TB) and hemophagocytic
lymphohistiocytosis (HLH). HLH is a rare hematological
disorder involving hyperactivation of macrophages and
lymphocytes, usually presenting in infancy. Adult-onset
HLH is rarer still and almost universally fatal without treat-
ment, with median survival of only 1.8–2.2months [10].
To our knowledge, this is the first documentation of a
patient presenting with EPC complicated by TB and HLH.
It is likely that such a copresentation is underdiagnosed,
given the complexities of making each diagnosis. The
lessons learned are likely to be relevant to general phy-
sicians, who are most likely to encounter such a patient
first, as well as to the various medical specialties likely
to share the ongoing care of such a patient, including
neurology, infectious diseases, and hematology.
Case presentation
A 54-year-old black South African woman was admitted
to a local hospital in Scotland following several months
of episodic night sweats, feverishness, and unexplained
weight loss. She then developed frequent episodes of
right-sided facial and arm “twitching” with preserved
consciousness. These episodes progressively became
constant and were exacerbated when she tried to talk.
They persisted through sleep. She also complained of
progressive breathlessness at rest. She recalled being
treated for TB over 20 years previously, in the late
1980s, when she had been living in South Africa. Further
details of this were unavailable. Her past medical history
also included autoimmune neutropenia and mild anemia
that had required no intervention. She had no significant
family history. She worked in healthcare and did not
smoke tobacco or drink alcohol. Although she lived in
the United Kingdom, she visited South Africa each year.
Clinical examination revealed a persistent, low-grade
pyrexia and a purpuric rash. She was hemodynamically
stable, alert, and able to follow commands. She was tachyp-
neic, and on occasion she required inhaled oxygen support
to maintain oxygen saturation at 92–94%. She had
continuous, semirhythmic contractions in the muscles on
the right side of her face. These movements extended from
her mouth to her eyebrows (Additional file 1: Video S1).
She had no other neurological deficits, and the remainder
of her general examination was unremarkable. A summary
of various investigations carried out and the differential
diagnoses that were considered is shown in Table 1.
An in-depth timeline of the patient’s inpatient course
is provided in Additional file 2: Table S1. She was
initially suspected of having meningococcal septicemia,
owing to her purpuric rash and pyrexia, and she was
commenced on 2 g daily of intravenous (IV) ceftriaxone.
Her condition then deteriorated rapidly into acute
respiratory failure with new bilateral perihilar opacifi-
cation evident on chest imaging (Fig. 1), requiring a short
period of intensive care for noninvasive ventilation. Ceftri-
axone was stopped following negative blood culture
results and suspicion that marked thrombocytopenia (low-
est platelet count 3 × 109/L) explained her purpura. IV
co-trimoxazole 120mg/kg daily was commenced to treat
Pneumocystis pneumonia (PCP), and she also received 2 g
of meropenem four times daily for 7 days for ongoing
pyrexia. She had blood, urine, sputum, and cerebrospinal
fluid cultures for mycobacteria. These each isolated
Mycobacterium tuberculosis. Her pancytopenia and hy-
perferritinemia prompted bone marrow investigation. A
marrow aspirate revealed macrophage activation and
hemophagocytosis, supporting a diagnosis of HLH (Fig. 2).
A trephine biopsy identified numerous caseating epitheli-
oid granulomata, supporting a diagnosis of TB. Her
twitching was investigated with magnetic resonance im-
aging (MRI) of the brain (with and without contrast). This
revealed four small contrast-enhancing foci within the
parenchyma of the brain. These were interpreted as likely
tuberculomas. One of the lesions was located on the
motor strip of her left hemisphere (Fig. 3). This location
corresponds somatotopically with her right-sided abnor-
mal facial movements. A clinical diagnosis of EPC was
made. Electroencephalography (EEG) revealed muscle
artefact but was otherwise normal (Fig. 4). Given the wide-
spread evidence of tuberculous disease, a diagnosis of
disseminated TB was made.
10 mg boluses of IV diazepam were initially given and
failed to reduce her continuous focal seizure activity. IV le-
vetiracetam 750mg daily was then added but demon-
strated minimal effect. She was therefore given 10 mg
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Table 1 Summary of investigations
Investigation Results Differential diagnosis
Peripheral blood
investigations
Pancytopenia: Hemoglobin 86 g/L, mean cell volume 86 fL, white cell
count 0.1 × 109/L (neutrophil count 0.00 × 109/L, lymphocyte count
0.17 × 109/L), platelets 18 × 109/L, low natural killer cell levels
(at 6% detected in an HIV immunology screen)
Raised ferritin: 127,985 μg/L
Raised C-reactive protein: 123 mg/L
Abnormal liver function: Bilirubin 22 μmol/L, alkaline phosphatase
219 U/L, alanine aminotransferase 27 U/L, γ-glutamyl transferase
356 U/L
Raised lactate dehydrogenase: 2567 U/L
Normal renal function: Sodium 143mmol/L, potassium 4.3 mmol/L,
urea 4.0 mmol/L, creatinine 52 μmol/L
Normal clotting: Prothrombin time 14 seconds, activated partial
thromboplastin time 29 seconds, fibrinogen 2.4 g/L
Negative HIV test
Positive antinuclear antibody and positive anti-Ro (> 100.0 U/mL),
negative anti-LA/Sm/Scl70/Jo1
Hemophagocytic lymphohistiocytosis
Autoimmune disease (for example, systemic lupus
erythematosus or Sjögren’s syndrome, which may
cause macrophage activation syndrome)
Infection/sepsis
Aplastic anemia (for example, idiopathic)
Marrow infiltration (for example, acute leukemias)
Thrombotic thrombocytopenic purpura, hemolytic
uremic syndrome
X-ray Chest x-ray (Fig. 1): Bilateral perihilar opacification Pneumocystis pneumonia
Atypical pneumonia
Hypersensitivity pneumonitis
Pulmonary tuberculosis
Computed tomography CT of the chest, abdomen, and pelvis with contrast: Abnormal
lungs with widespread acinar ground glass opacification,
intralobular thickening, and nodular change in a predominantly
perihilar distribution. A moderate-sized right pleural effusion
was noted. There were no enlarged axillary, supraclavicular, or
mediastinal lymph nodes. There was no evidence of pulmonary
embolism. Acalculous cholecystitis was noted.
Pulmonary tuberculosis
Lymphoma
Sarcoidosis
Lumbar puncture LP opening pressure not recorded; routine CSF was
unremarkable with protein of 0.62 g/L, no white cells,
and glucose 3.0 mmol/L (paired serum glucose not recorded).
Nondiagnostic routine CSF biochemistry
and cell counts
Microbiology Routine cultures (blood, urine, sputum, CSF): No growth
Pneumocystis jirovecii PCR negative, Legionella antigen and PCR
negative, respiratory mycology negative, routine respiratory
culture negative
Mycobacterial cultures positive (blood, urine, sputum, CSF):
Mycobacterium tuberculosis
Disseminated Mycobacterium tuberculosis
Note: Acellular CSF in CNS tuberculosis is
possible and well-described [11]
Abbreviations: g Grams, L liter, HIV Human immunodeficiency virus, μg Microgram, mg Milligram, μmol Micromole, U Units, mmol Millimoles, mL milliliter, CT
Computed tomography, TB Tuberculosis, LP Lumbar puncture, CSF Cerebrospinal fluid, PCR Polymerase chain reaction, CNS Central nervous system
Fig. 1 Chest x-ray. a Anterior-posterior (AP) film obtained on admission demonstrating normal heart, lung, mediastinum, and bony thorax shadows.
b Posterior-anterior (PA) film obtained on day 4 of admission to investigate the patient’s acute respiratory failure. The film demonstrates
extensive new bilateral acinar opacification in a mainly perihilar distribution throughout all lobes of both lungs in a fairly symmetrical distribution.
Normal cardiac contours and pulmonary vascularity are seen
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boluses of buccal midazolam and loaded with IV phenytoin
at a dose of 17mg/kg/day. When these were unsuccessful
in stopping the seizures, IV levetiracetam was uptitrated to
2500mg daily, and the IV phenytoin was uptitrated to 550
mg daily. She was also commenced on 1mg of regular oral
clonazepam daily. Her seizures stopped while she was re-
ceiving these three medications. She had experienced 7
days of unbroken focal seizure activity in total. A residual
right-sided Todd’s paresis was noted, which soon resolved.
She required high doses of oral antiepileptic drug (AED)
polytherapy to maintain seizure freedom (clobazam 10mg
twice daily, levetiracetam 1500mg twice daily, and pheny-
toin 350mg once daily). Reducing or changing her AEDs
proved difficult, with attempts to do so resulting in the re-
emergence of EPC seizures. Interval MRI of the brain with
contrast demonstrated an increased number of enhancing
parenchymal foci in keeping with tuberculomata scattered
throughout her brain (Fig. 5).
Fig. 2 Wright-Giemsa-stained bone marrow aspirate smear. 1 = neutrophil; 2 =myelocyte; 3 = promyelocyte; 4 = lymphocyte; 5 = erythroid precursors
at various stages of maturation. The white arrow points to an activated macrophage demonstrating hemophagocytosis of an erythroid precursor
Fig. 3 Axial T1 magnetic resonance image of the brain. a Precontrast. b Postcontrast. A small white focus is seen on the motor strip within the
left hemisphere after contrast is added (white arrow). The same area is unremarkable before contrast. This contrast-enhancing lesion is a probable
tuberculoma. The location of this lesion corresponds to the patient’s right-sided epilepsia partialis continua seizures
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The patient was commenced on a 12-month regimen
of oral anti-TB therapy as 6 months of once-daily isonia-
zid 300mg, rifampicin 600 mg, pyrazinamide 2mg, and
ethambutol 1000mg, then 10 months of the isoniazid
and rifampicin. Eight weeks of IV etoposide 150 mg/m2
were given for HLH (twice weekly for the first 2 weeks,
then once weekly for weeks 3–8). Long-term oral
steroids were given alongside etoposide as a dexametha-
sone taper from 18mg once daily over 8 weeks. Follo-
wing this, prednisolone was commenced at a 20-mg-daily
dose for the duration of anti-TB therapy. Overall, the
patient had remained hospitalized for 6 months due to
ongoing episodes of unwellness with fevers, respiratory
distress (requiring a second brief admission to intensive
care, for invasive ventilation), physical mobility problems,
and difficulties with memory and speech. During this
period, repeated sets of cultures, including blood, urine,
sputum, viral throat swabs, blood-borne viruses, and
repeat imaging, including of the chest, abdomen, pelvis,
and brain, failed to identify a cause of her ongoing pyrexia.
A repeat bone marrow aspiration, however, demonstrated
ongoing hemophagocytosis, and her ferritin levels
remained markedly elevated. Her pyrexia was therefore
believed to be a result of ongoing active HLH. She was
commenced on long-term oral cyclosporine 250mg twice
daily with a target of normalization of the ferritin levels,
which took 12months. Prednisolone was tapered slowly
during this period. The result of her immunologic screen-
ing for primary HLH with a granule release assay and
perforin expression studies was negative, and she therefore
did not undergo further HLH genetic study in light of
Fig. 4 Routine electroencephalogram obtained during the patient’s epilepsia partialis continua symptoms showing muscle artefact
Fig. 5 Interval postcontrast axial T1 magnetic resonance images of
the brain. These demonstrate many more small white foci
(tuberculomata) scattered throughout the brain, particularly in the
cerebellar (a) and cerebral (b–d) parenchyma. Most are 1–2 mm in
diameter. A small white focus remains seen on the motor strip
within the left hemisphere, corresponding to the patient’s right-
sided epilepsia partialis continua seizures
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these results and the increased likelihood that she had
HLH secondary to TB. To investigate the possibility of an
underlying susceptibility to disseminated TB, the patient
had a cytokine profile (including interferon-γ, interleukin
12, and tumor necrosis factor) and GATA2 gene mutation
screening, which returned normal results. A biopsy of the
lesions in the brain was considered in order to help
further characterize the pathological etiology of her
seizures, but the risks were believed to outweigh the bene-
fits because she had responded to AEDs and was receiving
treatment for both TB and HLH.
Upon discharge, she was seizure-free and experienced a
gradual improvement in function, although she remained
unable to work and required intensive outpatient func-
tional rehabilitation. She had negative repeat fluid culture
results for M. tuberculosis, and she was no longer pyrexic
or pancytopenic, although her ferritin remained elevated.
Her first 12months of outpatient recovery, during which
she completed oral anti-TB treatment, were complicated
by five brief readmissions to the hospital with relapses of
EPC seizures. Interval MRI scans of the brain during this
period demonstrated a gradual reduction and resolution
in the number of tuberculomata and progressive atrophy
of the left temporal, parietal, and occipital lobes. Her
seizure frequency gradually improved over the subsequent
3 years to one or two events per year, and she tolerated
stopping phenytoin and remaining on clobazam 10mg
twice daily and levetiracetam 1500mg twice daily. The
patient’s care required frequent collaboration between
neurology, infectious disease, and hematology specialists.
Discussion
Our patient experienced a complex and near-fatal course
of EPC, TB, and HLH requiring aggressive and prolonged
management. EPC is often a clue to serious underlying
pathology, and in our patient, failure to correctly identify
EPC could have resulted in the CNS tuberculomas being
missed (for example, through use of MRI without contrast
only) (see Fig. 3). Identification of the tuberculomas
guided the decision to lengthen TB eradication to 12
months and to prescribe adjuvant steroids [11]. In Add-
itional file 1, we provide a video demonstrating the pa-
tient’s seizures in order to help clinicians recognize the
possible semiology of EPC. EPC typically presents with a
prolonged period of repetitive muscle jerks to an entire
limb, with consciousness preserved. The movements re-
main uninterrupted throughout the day, worsen with ac-
tion, and continue during sleep. The symptoms can also
be sensory, presenting with continuous somatosensory,
proprioceptive, visual, auditory, olfactory, or gustatory
symptoms [2, 12]. A diagnosis of EPC should always be
made on clinical grounds [6]. EEG is normal in 20% of pa-
tients with EPC, and failure of EEG to demonstrate
epileptiform activity simply implies that the area of
cortical involvement is too small to record or is of a
subcortical origin (as seen in myoclonia continua) [1, 5,
6]. The underlying etiology of EPC in our patient was
most likely TB with CNS involvement.
The patient’s case was complicated by the co-occurrence
of EPC with TB and HLH. HLH is a rare hematological
syndrome that is almost universally fatal (owing to multi-
organ failure) without treatment [13]. HLH may have
been an additional driver, together with TB, of the
patient’s repeated respiratory failure episodes [14]. The
greatest barrier to prevention of mortality from HLH is
delay in diagnosis [15]. It is unlikely that our patient
would have survived her respiratory failure without
prompt recognition of the HLH and coinitiation of
chemotherapy alongside anti-TB therapy. A recent case
series of eight patients with TB-HLH reported four
cases of respiratory failure requiring invasive ventilation
and six deaths despite treatment [14]. HLH is charac-
terized by hemophagocytosis (phagocytosis of erythro-
cytes, leukocytes, platelets, and their precursors by
macrophages) [16, 17]. This is due to dysregulation of
activation and proliferation of macrophages in the bone
marrow and other tissues. Primary (familial) HLH has a
genetic etiology, whereas secondary HLH may be asso-
ciated with malignancy, autoimmune/rheumatological
disease (termed macrophage activation syndrome [MAS])
[17, 18], or infection [16, 17]. Although most infection-as-
sociated cases can be attributed to the Epstein-Barr virus,
TB-associated HLH is also recognized [16]. We propose
that in our patient, HLH was secondary to TB, giving rise
to a MAS [19–22]. Given her positive anti-Ro antibody, a
possible differential diagnosis was Sjögren’s syndrome
resulting in MAS, although clinically this was less likely.
HLH can present with fever, ataxia, and seizures [23].
Investigations may reveal splenomegaly, cytopenia,
hypertriglyceridemia, hemophagocytosis, low/absent
natural killer (NK) cell activity, raised ferritin, or ele-
vated interleukin 2 levels [24]. Various genetic muta-
tions may be found, including PRF1, UNC13D, STX11,
STXBP2, RAB27, and XLP [25]. Genetic testing is the gold
standard for diagnosing primary HLH. However, because
the results can take weeks to months, this test is not often
helpful in acutely differentiating primary from secondary
HLH [26]. Immunological screening investigations, as
were done for our patient, greatly facilitate this diagnostic
process because they can quickly diagnose and categorize
patients with primary HLH. The available immunological
tests include NK cell function testing, perforin expression
testing, and measurement of CD107a upregulation to
evaluate NK cell degranulation [26]. MRI of the brain in
HLH may show discrete nodular enhancing parenchymal
lesions [27]. It remains possible, therefore, that seizures in
our patient were potentiated by HLH, particularly if find-
ings on her MRI could be coattributed to HLH. The only
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way to resolve this would have been to obtain a lesional
biopsy of the brain, which was decided against on clinical
grounds and by patient choice.
There have been a small number of studies reporting
the co-occurrence of EPC and TB, identifying ten
patients (summarized in Additional file 3: Table S2)
[5, 9, 28, 29]. Taken together with our patient’s case,
the evidence suggests TB can cause EPC through a
mechanism of vasculitic infarctions or a mechanism
of tuberculoma formation. The reported duration of
EPC in TB typically ranges from hours to 10 days.
The mainstay of treating EPC is to focus therapy on
the underlying condition [1]. In their case report,
Bataduwaarachchi et al. [28] were able to terminate
seizures by eradicating TB using a 2-month induction
of oral isoniazid, rifampicin, pyrazinamide, and intra-
muscular streptomycin, followed by 10months of isonia-
zid and rifampicin. Adjunctive steroids were given as IV
methylprednisolone pulses for 3 days, followed by a
1-month oral taper. AEDs were 200mg of sodium valpro-
ate given three times daily and 10mg of clobazam given
twice daily. The remaining studies did not specifically
report how TB was eradicated or whether this reduced the
EPC seizures. All patients required high doses of AEDs. In
the context of this limited pool of evidence describing
how to specifically manage EPC caused by TB, we have
been able to provide anecdotal corroborative evidence that
a 12-month anti-TB therapy and steroid regimen [11] can
be effective in eradicating TB and reducing seizures in
EPC, alongside high doses of AEDs. We await other docu-
mented reports of EPC complicated by TB and HLH.
Indeed, although there is an association between HLH
and epilepsy, EPC-associated HLH is also yet to be
reported. Limited evidence surrounding the coexpression
of these three diseases may represent absolute rarity,
underdiagnosis, or incomplete case ascertainment due to
early death of untreated TB or HLH.
There are few prospective trials guiding the treatment
of HLH in adults [30], and treatment has been based
largely on the HLH-94 study on children aged < 16 years
with primary HLH [13, 31]. This highlights the rarity of
HLH in adults. Anecdotally, HLH chemotherapy might
be avoidable in secondary HLH, when the patient is well,
by treating the underlying cause only [15]. This was not
the case for our patient, and she required treatment with
the HLH-94 protocol (8 weeks of etoposide and dexa-
methasone followed by cyclosporine and oral steroids).
This protocol is normally used as a bridge to allogenic
hematopoietic cell transplantation in primary HLH,
whereas secondary HLH normally depends on success-
fully treating the underlying cause [31]. Our patient
demonstrated no further evidence of TB, but it took a
long time for her hyperferritinemia to settle following
TB eradication. In this context, it became difficult to
know how long cyclosporine and steroids should have
been continued, another area lacking evidence. The
more recent HLH-2004 trial used only adjuvant cyclo-
sporine with etoposide and dexamethasone in children
with HLH aged < 18 years for a total of 8 weeks [32]. It
is possible that the cyclosporine potentiated our patient’s
seizures, because these are known side effects of the
drug. However, the benefits of treating HLH aggressively
in our patient, given how unwell she had been in associ-
ation with this disease, were believed to outweigh the
risks of triggering an ongoing focal epilepsy that had
been therapy-responsive, did not generalize, and did not
compromise her airway (and therefore was more benign
than uncontrolled and potentially fatal HLH). The
other drugs that have been tried in HLH are equally
or potentially more toxic than cyclosporine and in-
clude a combination of cyclophosphamide, vincristine,
and prednisone [33]; a combination of cyclophospha-
mide, doxorubicin, vincristine, and prednisolone
(CHOP) [34]; or doxorubicin, etoposide, and methyl-
prednisolone (DEP) [30]. In the context of a scant
evidence base, treating HLH and EPC is likely to be
complex in all cases, and it will be important for
clinicians to talk through the potential risks and ben-
efits carefully with patients in helping them come to
a decision on their preferred therapeutic avenue.
From a public health perspective, the case highlights
some of the difficulties in ascertaining a complete his-
tory of TB exposure, completed therapy, or documented
eradication for clinicians seeing patients in whom expo-
sure is historic and within resource-poor settings. Our
patient’s recollected experience of TB and TB therapy
dated back to more than 20 years prior, during the apart-
heid era of South Africa, when healthcare provision and
documentation for black Africans was very poor [35].
For all patients who are healthcare workers in Scotland,
mandatory checks for TB disease/immunity are com-
pleted before clinical duties are allowed to commence
[36]. They include assessment of personal or family
history of TB, tuberculin skin testing (or interferon-γ
testing) plus or minus bacillus Calmette–Guérin vacci-
nation where required, and routine chest x-ray for those
from high-risk countries, plus or minus TB treatment if
indicated. Further details are provided in the Scottish
Government document “Health Clearance for Tubercu-
losis, Hepatitis B, Hepatitis C and HIV for New Health-
care Workers with Direct Clinical Contact with Patient”
[36]. This policy applies to all NHS Scotland healthcare
workers having direct clinical contact with patients,
including new or returning healthcare workers, and
healthcare workers changing to a new NHS employer
(unless providing valid evidence of screening from their
previous NHS employer). The policy was introduced in
2008. In our patient’s specific case, she began working
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for NHS Scotland prior to this date and was not
screened for TB. She did have a baseline chest x-ray that
demonstrated nothing to suggest past infection with TB
(Fig. 1). However, it remains unclear if her TB mani-
fested as a new infection or as reactivation of latent
TB. If the case were the latter, it would suggest a
potential for value in prospectively screening health-
care workers employed in Scotland prior to 2008 if
they have not already been screened through existing
mechanisms. Overall, there remains a significantly
increased risk of both latent TB and active TB in
healthcare workers worldwide compared with the
general population [37].
Conclusions
We describe the complex interdisciplinary case of a
patient presenting with episodic feverishness, continu-
ous facial twitching, and pancytopenia. She has been
diagnosed with EPC complicated by TB and HLH.
These are difficult diagnoses to make, and we provide
clinicians with a helpful video of the patient’s EPC
seizures and annotated images of the hemophago-
cytosis viewed on marrow aspirate. The case educates
clinicians to persist with investigating for an under-
lying cause when presented with a patient with EPC
(including the importance of using contrast on the
MRI brain scan if an unenhanced scan is unremark-
able). It also educates clinicians not to forget to in-
vestigate for HLH when faced with a patient with TB
presenting with pancytopenia, and it is a reminder
that HLH, although usually a pediatric condition, can
occur in adults. Although HLH is rare, its very high
mortality makes this an important diagnosis not to
miss. Clinicians faced with these patients may wish to
try a prolonged oral TB eradication schedule (12
months), alongside HLH-specific chemotherapy with 8
weeks of etoposide and dexamethasone. If there re-
mains evidence of HLH disease activity (we used fer-
ritin as the marker), our patient’s case suggests that a
maintenance combination of cyclosporine and pred-
nisolone may be helpful. This case also suggests that
escalating doses of parenteral benzodiazepines, leveti-
racetam, and phenytoin initially, followed by continu-
ing high doses of these AEDs orally, may be helpful
in managing EPC in a patient with TB and HLH. This
is a rare combination of disease, and this report encour-
ages clinicians to remain vigilant about this syndrome,
and it should help stimulate further research on the
most effective way to manage these patients. The
management avenues we tried were helpful anec-
dotally but would require validation as part of a con-
trolled interventional trial on patients with TB, EPC,
and HLH, which is yet to be done.
Additional files
Additional file 1: Video S1. Audio-free video of the patient during
epilepsia partialis continua (EPC) seizures. This video was taken during the
epilepsia partialis continua (EPC) symptoms, with scalp electroencephalogram
(EEG) recording electrodes worn. The video shows that the patient had
continuous, stereotyped, right-sided, semirhythmic, contractions in the
muscles of the face. These extended from the mouth to the eyebrow. The
patient was alert and able to communicate throughout the recording. The
differential diagnosis includes cortical myoclonus, which is similarly
exacerbated by movement but would normally affect the limbs more
diffusely [4]. It also includes generalized epileptic myoclonus (for
example, in juvenile myoclonic epilepsy), in which an accompanying
history of generalized tonic-clonic seizures and generalized epileptiform
discharges on EEG would have been expected [38]. Tremor may look
similar to EPC but the larger amplitude in EPC usually distinguishes the
two types of movements. Tremor is unlikely to continue during sleep.
(MP4 778 kb)
Additional file 2: Table S1. Clinical details and timeline of the patient’s
inpatient journey. A timeline detailing the patient’s inpatient journey,
including clinical features, investigations, and management. (DOCX 23 kb)
Additional file 3: Table S2. Summary of published studies reporting
the co-occurrence of epilepsia partialis continua (EPC) and tuberculosis
(TB). A case series summarized from the published studies reporting the
co-occurrence of epilepsia partialis continua (EPC) and tuberculosis (TB).
(DOCX 21 kb)
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